Sign In to Follow Application
View All Documents & Correspondence

Conjugates Of An Il 7 Moiety And An Polymer

Abstract: Conjugates of an IL 7 moiety and one or more nonpeptidic water soluble polymers are provided. Typically the nonpeptidic water soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided among other things are compositions comprising conjugates methods of making conjugates and methods of administering compositions to an individual.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
07 September 2017
Publication Number
37/2017
Publication Type
INA
Invention Field
PHARMACEUTICALS
Status
Email
Parent Application
Patent Number
Legal Status
Grant Date
2023-03-17
Renewal Date

Applicants

NEKTAR THERAPEUTICS
455 Mission Bay Boulevard, South, Suite 100, San Francisco, California 94158

Inventors

1. CHARYCH, Deborah, H.
909 Taylor Avenue, Albany , CA 94706
2. ZHANG, Ping
5 Madrid Court, Millbrae, CA 94030
3. KIRK, Peter, Benedict
413 Poinsettia Avenue, San Mateo, CA 94403

Specification

What is claimed is;
1. A conjugate comprising a residue of an IL-7 moiety covalently attached to a water-soluble polymer.
2. The conjugate of claim 1, wherein the IL-7 moiety covalently attached to the water-soluble polymer is covalently attached via a releasable linkage.
3. The conjugate of claim 1, wherein the IL-7 moiety covalently attached to the water-soluble polymer is covalently attached via a stable linkage.
4. The conjugate of any one of claims 1, 2 and 3, wherein the water-soluble polymer is a branched water-soluble polymer.
5. The conjugate of any one of claims 1, 2, 3 and 4, wherein the water-soluble polymer is a polymer selected from the group consisting of poly(alkylene oxide), poly (vinyl pyrrolidone), poly(vinyl alcohol), polyoxazoline, and poly(acryloylmorpholine).
6. The conjugate of claim 5, wherein the water-soluble polymer is a poly(alkylene oxide).
7. The conjugate of claim 6, wherein the poly(alkylene oxide) is a poly(ethylene glycol).
8. The conjugate of claim 7, wherein the poly(ethylene glycol) is terminally capped with an end-capping moiety selected from the group consisting of hydroxy, alkoxy, substituted alkoxy, alkenoxy, substituted alkenoxy, alkynoxy, substituted alkynoxy, aryloxy and substituted aryloxy.
9. The conjugate of any one of claims 1, 2, 3, 4, 5, 6 and 7, wherein the water-soluble polymer has a weight-average molecular weight in a range of from about 500 Daltons to about 100,000 Daltons.

10. The conjugate of any one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, wherein the conjugate is covalently attached at an amine group of the residue of the IL-7 moiety.
11. The conjugate of any one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, wherein one, two, three or four water-soluble polymers are attached to the residue of the IL-7 moiety.
12. The conjugate of any one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, wherein one, two or three water-soluble polymers are attached to the residue of the IL-7 moiety.
13. The conjugate of any one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, wherein one or two water-soluble polymers are attached to the residue of the IL-7 moiety.
14. The conjugate of any one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, wherein one water-soluble polymer is attached to the residue of the IL-7 moiety.
15. The conjugate of any one of the proceedings claims, wherein the IL-7 moiety has an amino acid sequence selected from the group consisting of SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; and SEQ ID NO: 8.
16. A conjugate comprising a residue of an IL-7 moiety covalently attached to a water-soluble polymer, wherein the water-soluble polymer, prior to being covalently attached, is a polymeric reagent bearing an N-hydroxysuccinimidyl group.
17. A pharmaceutical composition comprising a conjugate of any one of claims 1 through 16 and a pharmaceutically acceptable excipient.
18. A method comprising administering to an individual a pharmaceutical composition of claim 17.
19. A method for making a conjugate comprising contacting, under conjugation conditions, an IL-7 moiety with a polymeric reagent.

Documents

Application Documents

# Name Date
1 201747031687-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [07-09-2017(online)].pdf 2017-09-07
2 201747031687-STATEMENT OF UNDERTAKING (FORM 3) [07-09-2017(online)].pdf 2017-09-07
3 201747031687-SEQUENCE LISTING(PDF) [07-09-2017(online)].pdf 2017-09-07
4 201747031687-SEQUENCE LISTING [07-09-2017(online)].pdf 2017-09-07
5 201747031687-PRIORITY DOCUMENTS [07-09-2017(online)].pdf 2017-09-07
6 201747031687-FORM 1 [07-09-2017(online)].pdf 2017-09-07
7 201747031687-DRAWINGS [07-09-2017(online)].pdf 2017-09-07
8 201747031687-DECLARATION OF INVENTORSHIP (FORM 5) [07-09-2017(online)].pdf 2017-09-07
9 201747031687-COMPLETE SPECIFICATION [07-09-2017(online)].pdf 2017-09-07
10 201747031687-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [07-09-2017(online)].pdf 2017-09-07
11 201747031687.pdf 2017-09-09
12 abstract 201747031687.jpg 2017-09-11
13 201747031687-Proof of Right (MANDATORY) [08-11-2017(online)].pdf 2017-11-08
14 201747031687-FORM-26 [08-11-2017(online)].pdf 2017-11-08
15 201747031687-FORM 3 [08-11-2017(online)].pdf 2017-11-08
16 Correspondence by Agent_Proof of Right,Power of Attorney_09-11-2017.pdf 2017-11-09
17 201747031687-FORM 18 [22-12-2017(online)].pdf 2017-12-22
18 201747031687-FER.pdf 2020-01-30
19 201747031687-FORM 4(ii) [29-07-2020(online)].pdf 2020-07-29
20 201747031687-OTHERS [30-10-2020(online)].pdf 2020-10-30
21 201747031687-FORM 3 [30-10-2020(online)].pdf 2020-10-30
22 201747031687-FER_SER_REPLY [30-10-2020(online)].pdf 2020-10-30
23 201747031687-DRAWING [30-10-2020(online)].pdf 2020-10-30
24 201747031687-COMPLETE SPECIFICATION [30-10-2020(online)].pdf 2020-10-30
25 201747031687-CLAIMS [30-10-2020(online)].pdf 2020-10-30
26 201747031687-Annexure [30-10-2020(online)].pdf 2020-10-30
27 201747031687-ABSTRACT [30-10-2020(online)].pdf 2020-10-30
28 201747031687-US(14)-HearingNotice-(HearingDate-25-01-2023).pdf 2023-01-05
29 201747031687-REQUEST FOR ADJOURNMENT OF HEARING UNDER RULE 129A [20-01-2023(online)].pdf 2023-01-20
30 201747031687-US(14)-ExtendedHearingNotice-(HearingDate-22-02-2023).pdf 2023-01-23
31 201747031687-Correspondence to notify the Controller [17-02-2023(online)].pdf 2023-02-17
32 201747031687-Written submissions and relevant documents [09-03-2023(online)].pdf 2023-03-09
33 201747031687-Retyped Pages under Rule 14(1) [09-03-2023(online)].pdf 2023-03-09
34 201747031687-FORM 13 [09-03-2023(online)].pdf 2023-03-09
35 201747031687-Annexure [09-03-2023(online)].pdf 2023-03-09
36 201747031687-Annexure [09-03-2023(online)]-1.pdf 2023-03-09
37 201747031687-2. Marked Copy under Rule 14(2) [09-03-2023(online)].pdf 2023-03-09
38 201747031687-PatentCertificate17-03-2023.pdf 2023-03-17
39 201747031687-IntimationOfGrant17-03-2023.pdf 2023-03-17
40 201747031687-RELEVANT DOCUMENTS [29-09-2023(online)].pdf 2023-09-29

Search Strategy

1 strategy_1687_29-01-2020.pdf

ERegister / Renewals

3rd: 30 Mar 2023

From 11/03/2018 - To 11/03/2019

4th: 30 Mar 2023

From 11/03/2019 - To 11/03/2020

5th: 30 Mar 2023

From 11/03/2020 - To 11/03/2021

6th: 30 Mar 2023

From 11/03/2021 - To 11/03/2022

7th: 30 Mar 2023

From 11/03/2022 - To 11/03/2023

8th: 30 Mar 2023

From 11/03/2023 - To 11/03/2024

9th: 23 Feb 2024

From 11/03/2024 - To 11/03/2025

10th: 24 Feb 2025

From 11/03/2025 - To 11/03/2026